Language Settings
My query is:

Combine searches by placing the search numbers in the top search box and pressing the search button.
An example search might look like (#1 or #2) and (#3 or #4)

Loading history...

Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

141. Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life

Evidence-Based Nursing (Requires free registration)2013

142. Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia

Evidence-Based Mental Health2013

143. Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice

Evidence-Based Mental Health2013

144. Death rate in older people with schizophrenia elevated compared with the general population

Evidence-Based Mental Health2013

145. Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

National Institute for Health and Clinical Excellence - Technology Appraisals2013

146. The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age

Evidence-Based Mental Health2013

147. Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population

Evidence-Based Mental Health2013

148. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Evidence-Based Mental Health2013

149. Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics

Evidence-Based Mental Health2013

150. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia

Evidence-Based Mental Health2013

151. Schizophrenia: omega-3 fatty acid medicines

National Institute for Health and Clinical Excellence - Advice2013

152. Psychosis and schizophrenia in children and young people: recognition and management

National Institute for Health and Clinical Excellence - Clinical Guidelines2013

153. Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia

DARE.2012

154. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

DARE.2012

155. Flupenthixol versus placebo for schizophrenia.

Cochrane2012

156. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia

EvidenceUpdates2012

157. Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics

Health Technology Assessment (HTA) Database.2012

158. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia

NHS Economic Evaluation Database.2012

159. Asenapine - Schizophrenia

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2012

160. Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE)

NIHR HTA programme2012